Skip to Main Content

Paper Details

Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
J Urol
29
2018
Author NameAffiliation
Andrzej NiemierkoMassachusetts General Hospital
  • 1 - 1

Datasets

Release 1.2